Research progress of prognostic biomarkers in diffuse large B-cell lymphoma].

H Z Chen, Y K Shi

Zhonghua zhong liu za zhi [Chinese journal of oncology] 2020 Dec 23

filter terms:

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous malignancy. A variety of indicators have been identified to predict the prognosis of DLBCL. However, with the emerging new drugs and new therapeutic options in recent years, the prognostic value of these risk prediction models becomes limited, failing to accurately guide treatment. The rapid development of high throughput technologies has led to dramatic improvement in understanding of the biology of DLBCL. The emergence of various new biomarkers contributes to further understanding the pathogenesis, treatment optimization and prognostic stratification of this disease. This review summarizes the prognostic biomarkers related to DLBCL, which mainly covers the hematological, genetic and tumor microenvironment factors, aiming to provide some theoretical basis for the precision treatment of DLBCL.

Citation

H Z Chen, Y K Shi. Research progress of prognostic biomarkers in diffuse large B-cell lymphoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2020 Dec 23;42(12):989-995